Oregon Health and Science University
OHSU Knight Cancer Institute
Portland, OR
Filters
Save & Share
Clear Filters
Diagnosis
Treatment History
Not yet accepting
CARTITUDE-2
Phase 2, Open-Label Study Evaluating the Use of an Investigational CAR-T Cell therapy in Participants with Multiple Myeloma
Learn more- CAR T Cell
- BCMA
- Phase 2
Not yet accepting
QUINTESSENTIAL
Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
Learn more- CAR T Cell
- GPRC5D
- Phase 2
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trialsNot yet accepting
EXCALIBER RRMM
Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Iberdomide, Daratumumab and Dexamethasone VS Daratumumab, Bortezomib, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Learn more- CELMoD
- Randomization
- Phase 3
Accepting patients
DREAMM12
A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Participants With Normal and Varying Degrees of Impaired Renal Function
Learn more- Antibody Drug Conjugate (ADC)
- BCMA
- Phase 1
Accepting patients
RedirecTT-1
A Phase 1b/2 Dose Escalation and Expansion Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Learn more- Bispecific Antibody
- GPRC5D
- Phase 1/2
Accepting patients
CAMPERR
cfDNA Assay Multicenter Prospective Observational Validation for Early Cancer Detection, Minimal Residual Disease, and Relapse
Learn more- Observational Trial
Accepting patients
DRAMMATIC
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
Learn more- Monoclonal Antibody
- CD38
- Maintenance
- Phase 3
Not yet accepting
MajesTEC-7
A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)
Learn more- Bispecific Antibody
- BCMA
- Randomization
- Phase 3
Accepting patients
iMMAGINE-1
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma
Learn more- CAR T Cell
- BCMA
- Phase 2
Accepting patients
EQUATE
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Learn more- Monoclonal Antibody
- CD38
- Phase 3